Cargando…

Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation

OBJECTIVE: The objectives of this study were to evaluate whether dose to the vasculature is associated with local control after surgery in patients with borderline resectable (BLR) and resectable pancreatic cancer (PCA) receiving neoadjuvant radiation therapy (RT) and to identify a dose threshold fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelson, Bailey, Barrord, Michelle, Wang, Kyle, Wages, Nolan A., Sudhoff, Mickaela, Kharofa, Jordan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470914/ https://www.ncbi.nlm.nih.gov/pubmed/36119519 http://dx.doi.org/10.3389/fonc.2022.906484

Ejemplares similares

The value of hybrid interstitial tandem and ring applicators for organ at risk dose reduction in small volume cervical cancer
por: Crossley, Najeeb, et al.
Publicado: (2020)

Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
por: Wages, Nolan A., et al.
Publicado: (2022)

A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer
por: Cuneo, Kyle C., et al.
Publicado: (2014)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement
por: Lee, Jin Ho, et al.
Publicado: (2015)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
por: Galindo, José, et al.
Publicado: (2013)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy
por: Huang, Qunsheng, et al.
Publicado: (2019)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study()()
por: Dalah, Entesar, et al.
Publicado: (2018)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer
por: Ashida, Reiko, et al.
Publicado: (2020)

The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Buka, David, et al.
Publicado: (2017)

Neoadjuvant Chemoradiation Herapy for Soft Tissue Sarcomas of the Extremities
por: Aguiar, Samuel, et al.
Publicado: (2009)

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation
por: Dricken, Julie, et al.
Publicado: (2020)

Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021)

Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation
por: Nardone, Valerio, et al.
Publicado: (2019)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
por: Warnecke-Eberz, Ute, et al.
Publicado: (2020)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series
por: Gorbudhun, Rachna, et al.
Publicado: (2022)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance
por: Oria, V.O., et al.
Publicado: (2018)

Total laparoscopic and thoracoscopic Ivor Lewis esophagectomy after neoadjuvant Chemoradiation with minimal overall and anastomotic complications
por: Merritt, Robert E., et al.
Publicado: (2019)

Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
por: Liang, Jin-Tung, et al.
Publicado: (2017)

Neoadjuvant Concurrent Chemoradiation for Curative Treatment of Penile Squamous Cell Carcinoma
por: Chhabra, Arpit, et al.
Publicado: (2014)

Neoadjuvant chemoradiation for rectal cancer in patients aged 75 years or older
por: Lombardi, Raffaele, et al.
Publicado: (2009)

Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
por: Restivo, Angelo, et al.
Publicado: (2015)

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
por: Dayde, Delphine, et al.
Publicado: (2017)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

Neoadjuvant Chemoradiation Compared With Neoadjuvant Radiation Alone in the Management of High-Grade Soft Tissue Extremity Sarcomas
por: Hazell, Sarah Z., et al.
Publicado: (2019)

Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation
por: Kotha, Nikhil V., et al.
Publicado: (2021)

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
por: Katz, Matthew H. G., et al.
Publicado: (2010)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy
por: Hwang, Ho Kyoung, et al.
Publicado: (2020)

Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation
por: Shen, Lijun, et al.
Publicado: (2014)

Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks
por: Roh, Simon, et al.
Publicado: (2019)

Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma
por: Maas, Benjamin, et al.
Publicado: (2018)

Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation
por: Triantafyllou, Tania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kpqhp56llrmi39m794luqp07d1